Table 3.
Maximum CRS and ICANS in lymphoma cohort.
| Prophylactic G-CSFa (N = 140) | Controlb (N = 57) | Overall (N = 197) | |
|---|---|---|---|
| CRS gradec | |||
| 0 | 19 (13.6%) | 15 (26.3%) | 34 (17.3%) |
| 1 | 48 (34.3%) | 31 (54.4%) | 79 (40.1%) |
| 2 | 64 (45.7%) | 9 (15.8%) | 73 (37.1%) |
| 3 | 5 (3.6%) | 2 (3.5%) | 7 (3.6%) |
| 4 | 4 (2.9%) | 0 (0%) | 4 (2.0%) |
| ICANS gradec | |||
| 0 | 60 (42.9%) | 36 (63.2%) | 96 (48.7%) |
| 1 | 28 (20.0%) | 4 (7.0%) | 32 (16.2%) |
| 2 | 28 (20.0%) | 4 (7.0%) | 32 (16.2%) |
| 3 | 22 (15.7%) | 11 (19.3%) | 33 (16.8%) |
| 4 | 2 (1.4%) | 2 (3.5%) | 4 (2.0%) |
aProphylactic G-CSF refers to exposure to G-CSF prior to CAR T cell infusion.
bControl group includes patients who either received G-CSF after CAR T cell infusion (N = 42) or were not exposed to G-CSF (N = 15).
cMaximum CRS/ICANS grade per ASTCT consensus criteria.